Lin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lin Wang has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
Yuang Zhang
Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Shandong First Medical University & Shandong Academy of Medical Sciences; NHC Key Laboratory of Biotechnology Drugs, Shandong Academy of Medical Sciences; Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong, China
11 shared publicationsJihong Pan
Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Shandong First Medical University & Shandong Academy of Medical Sciences, Ji'nan, Shandong, 250117, China
9 shared publicationsLuna Ge
Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, NHC Key Laboratory of Biotechnology Drugs, Key Lab for Rare & Uncommon Diseases of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
9 shared publicationsRuojia Zhang
Biomedical Sciences College, Shandong Medicinal Biotechnology Centre, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
9 shared publicationsGuanhua Song
Department of Immunology, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China
7 shared publicationsTingting Feng
Biomedical Sciences College, Shandong Medicinal Biotechnology Centre, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
6 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
HAAO‑derived quinolinic acid fuels FDPS‑dependent AR signaling and sensitizes prostate cancer to combination therapy
Emerging evidence highlights that metabolic reprogramming profoundly shapes the tumor microenvironment and immune evasion in prostate cancer. However, the functional role and mechanisms of tryptophan metabolism in prostate cancer progression remain unclear. Through single-cell transcriptomic analysis, we identified one tumor cell subtype characterized by high expression of 3-hydroxyanthranilate 3,4-dioxygenase (HAAO) and enhanced kynurenine pathway activity. This subpopulation leads to the accumulation of quinolinic acid (QA), a metabolic intermediate that could activate the mevalonate (MVA) pathway. Mechanistically, QA directly binds to and stabilizes farnesyl diphosphate synthase (FDPS), a key MVA pathway enzyme, thereby enhancing cholesterol biosynthesis and fueling androgen receptor (AR)-driven transcriptional programs. This HAAO/QA-FDPS axis establishes a metabolic crosstalk that links tryptophan catabolism to lipid metabolism, sustaining prostate tumor progression. Furthermore, an integrated prognostic model incorporating this pathway signatures outperforms other clinical variables alone, and HAAO-high tumors exhibit heightened sensitivity to combined inhibition of the kynurenine and AR pathways. Our study unveils a novel metabolic vulnerability in prostate cancer and provides a mechanistic rationale for targeting the HAAO/QA-FDPS axis for therapy.
- 16 June 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Open AccessHAAO‑derived quinolinic acid fuels FDPS‑dependent AR signaling and sensitizes prostate cancer to combination therapy
Emerging evidence highlights that metabolic reprogramming profoundly shapes the tumor microenvironment and immune evasion in prostate cancer. However, the functional role and mechanisms of tryptophan metabolism in prostate cancer progression remain unclear. Through single-cell transcriptomic analysis, we identified one tumor cell subtype characterized by high expression of 3-hydroxyanthranilate 3,4-dioxygenase (HAAO) and enhanced kynurenine pathway activity. This subpopulation leads to the accumulation of quinolinic acid (QA), a metabolic intermediate that could activate the mevalonate (MVA) pathway. Mechanistically, QA directly binds to and stabilizes farnesyl diphosphate synthase (FDPS), a key MVA pathway enzyme, thereby enhancing cholesterol biosynthesis and fueling androgen receptor (AR)-driven transcriptional programs. This HAAO/QA-FDPS axis establishes a metabolic crosstalk that links tryptophan catabolism to lipid metabolism, sustaining prostate tumor progression. Furthermore, an integrated prognostic model incorporating this pathway signatures outperforms other clinical variables alone, and HAAO-high tumors exhibit heightened sensitivity to combined inhibition of the kynurenine and AR pathways. Our study unveils a novel metabolic vulnerability in prostate cancer and provides a mechanistic rationale for targeting the HAAO/QA-FDPS axis for therapy.
- Open Access
- 9 June 2026
- Published by Springer Nature in BMC Medical Education
Embedding Kolb’s experiential learning cycle in biotechnology education: a scientific experience before learning model
Basic experimental learning is a vital component of undergraduate studies. Based on Kolb's experiential learning cycle (ELC) theory, experiential learning is recognized as an effective teaching strategy for developing knowledge. In specialized courses, however, undergraduate students lack the necessary concrete experience for the first step of ELC. Hence, we construct a "scientific experience before learning" (SEBL) model using Kolb's ELC framework, which provides biotechnology undergraduate students with concrete, high-quality experiences based on a theoretical foundation that showed better ability to innovate. The students participating in the SEBL model showed improvements in their grade point average by ≥38.78 with average scores of 92.31% in specialized courses (1.976 ± 1.361 to 6.464 ± 2.349 points, p < 0.05). This improvement was associated with their development of experimental skills, as shown by innovative research achievements (e.g., 1.1 articles each, 26.83% patent applications, and 136.6% academic competition awards) compared with the control group (0.032 articles, 0% patent applications, and 11.29% awards, respectively). Meanwhile, the SEBL model was associated with higher undergraduate students' intention to pursue advanced degrees by 18% and was associated with higher admission to a master's degree by 32.76% (74.36%, SEBL group; 41.6%, non-SEBL group). Therefore, our proposed SEBL model design could be embedded into the ELC framework learning objectives to cultivate biotechnology talent.
- 9 June 2026
- Published by Springer Nature in BMC Medical Education
Open AccessEmbedding Kolb’s experiential learning cycle in biotechnology education: a scientific experience before learning model
Basic experimental learning is a vital component of undergraduate studies. Based on Kolb's experiential learning cycle (ELC) theory, experiential learning is recognized as an effective teaching strategy for developing knowledge. In specialized courses, however, undergraduate students lack the necessary concrete experience for the first step of ELC. Hence, we construct a "scientific experience before learning" (SEBL) model using Kolb's ELC framework, which provides biotechnology undergraduate students with concrete, high-quality experiences based on a theoretical foundation that showed better ability to innovate. The students participating in the SEBL model showed improvements in their grade point average by ≥38.78 with average scores of 92.31% in specialized courses (1.976 ± 1.361 to 6.464 ± 2.349 points, p < 0.05). This improvement was associated with their development of experimental skills, as shown by innovative research achievements (e.g., 1.1 articles each, 26.83% patent applications, and 136.6% academic competition awards) compared with the control group (0.032 articles, 0% patent applications, and 11.29% awards, respectively). Meanwhile, the SEBL model was associated with higher undergraduate students' intention to pursue advanced degrees by 18% and was associated with higher admission to a master's degree by 32.76% (74.36%, SEBL group; 41.6%, non-SEBL group). Therefore, our proposed SEBL model design could be embedded into the ELC framework learning objectives to cultivate biotechnology talent.
- Open Access
- 29 January 2026
- Published by Springer Nature in Research Square
Single-cell analysis reveals a kynurenine pathway enriched epithelial subpopulation and a HAAO/QA-FDPS metabolic axis in prostate cancer
Emerging evidence highlights that metabolic reprogramming profoundly shapes the tumor microenvironment and immune evasion in prostate cancer. However, the functional role and mechanisms of tryptophan metabolism in prostate cancer progression remain unclear. Through single-cell transcriptomic analysis, we identified one tumor cell subtype characterized by high expression of 3-hydroxyanthranilate 3,4-dioxygenase (HAAO) and enhanced kynurenine pathway activity. This subpopulation leads to the accumulation of quinolinic acid (QA), a metabolic intermediate that could activate the mevalonate (MVA) pathway. Mechanistically, QA directly binds to and stabilizes farnesyl diphosphate synthase (FDPS), a key MVA pathway enzyme, thereby enhancing cholesterol biosynthesis and fueling androgen receptor (AR)-driven transcriptional programs. This HAAO/QA-FDPS axis establishes a metabolic crosstalk that links tryptophan catabolism to lipid metabolism, sustaining prostate tumor progression. Furthermore, an integrated prognostic model incorporating this pathway signatures outperforms other clinical variables alone, and HAAO-high tumors exhibit heightened sensitivity to combined inhibition of the kynurenine and AR pathways. Our study unveils a novel metabolic vulnerability in prostate cancer and provides a mechanistic rationale for targeting the HAAO/QA-FDPS axis for therapy.
- 29 January 2026
- Published by Springer Nature in Research Square
Open AccessSingle-cell analysis reveals a kynurenine pathway enriched epithelial subpopulation and a HAAO/QA-FDPS metabolic axis in prostate cancer
Emerging evidence highlights that metabolic reprogramming profoundly shapes the tumor microenvironment and immune evasion in prostate cancer. However, the functional role and mechanisms of tryptophan metabolism in prostate cancer progression remain unclear. Through single-cell transcriptomic analysis, we identified one tumor cell subtype characterized by high expression of 3-hydroxyanthranilate 3,4-dioxygenase (HAAO) and enhanced kynurenine pathway activity. This subpopulation leads to the accumulation of quinolinic acid (QA), a metabolic intermediate that could activate the mevalonate (MVA) pathway. Mechanistically, QA directly binds to and stabilizes farnesyl diphosphate synthase (FDPS), a key MVA pathway enzyme, thereby enhancing cholesterol biosynthesis and fueling androgen receptor (AR)-driven transcriptional programs. This HAAO/QA-FDPS axis establishes a metabolic crosstalk that links tryptophan catabolism to lipid metabolism, sustaining prostate tumor progression. Furthermore, an integrated prognostic model incorporating this pathway signatures outperforms other clinical variables alone, and HAAO-high tumors exhibit heightened sensitivity to combined inhibition of the kynurenine and AR pathways. Our study unveils a novel metabolic vulnerability in prostate cancer and provides a mechanistic rationale for targeting the HAAO/QA-FDPS axis for therapy.
- 3 January 2026
- Published by Elsevier in Molecular Immunology
- Vol. 189, 235-246
Investigating the role of SMOX in rheumatoid arthritis
- 3 January 2026
- Published by Elsevier in Molecular Immunology
- Vol. 189, 235-246
Investigating the role of SMOX in rheumatoid arthritis
- Open Access
- 3 December 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (12) , e013733
NEAT1 is a therapeutic target for reversing T-cell exhaustion in bladder cancer
Background: T-cell exhaustion induced by the tumor microenvironment is an important factor in posing a major challenge to effective cancer immunotherapy. Immune checkpoint inhibitors aim to reverse T-cell exhaustion. However, the effectiveness of immune checkpoint inhibitors is often limited due to their off-target effects and single targets. Herein, we attempt to identify molecular targets that can regulate the expression of multiple immune checkpoints to reverse T-cell exhaustion. Methods: NSG mice with xenotransplantation of human bladder cancer cells were used to investigate the function of nuclear paraspeckle assembly transcript 1 (NEAT1) in T-cell exhaustion. Chromatin isolation by RNA purification, chromatin immunoprecipitation, and luciferase assays was employed to investigate the molecular mechanisms by which NEAT1 regulates expression of target genes. Results: NEAT1, a bladder cancer-related long non-coding RNA (lncRNA), promotes lactate production in tumor cells by binding to the lactate dehydrogenase A gene. This lactate production subsequently inhibits NEAT1 expression in CD8+T cells. Furthermore, NEAT1 in CD8+T cells plays a crucial role in modulating the immune response of CD8+T cells against tumor cells. Our findings indicate that NEAT1 regulates the expression of multiple immune checkpoint genes by directly binding to them and inhibiting transcription through the alteration of histone lactylation near transcriptional start sites, which affects RNA polymerase II recruitment. Conclusions: lncRNA NEAT1 serves as a modulator of the antitumor response of CD8+T cells in the bladder tumor microenvironment and may represent a therapeutic target for reversing T-cell exhaustion.
- 3 December 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (12) , e013733
Open AccessNEAT1 is a therapeutic target for reversing T-cell exhaustion in bladder cancer
Background: T-cell exhaustion induced by the tumor microenvironment is an important factor in posing a major challenge to effective cancer immunotherapy. Immune checkpoint inhibitors aim to reverse T-cell exhaustion. However, the effectiveness of immune checkpoint inhibitors is often limited due to their off-target effects and single targets. Herein, we attempt to identify molecular targets that can regulate the expression of multiple immune checkpoints to reverse T-cell exhaustion. Methods: NSG mice with xenotransplantation of human bladder cancer cells were used to investigate the function of nuclear paraspeckle assembly transcript 1 (NEAT1) in T-cell exhaustion. Chromatin isolation by RNA purification, chromatin immunoprecipitation, and luciferase assays was employed to investigate the molecular mechanisms by which NEAT1 regulates expression of target genes. Results: NEAT1, a bladder cancer-related long non-coding RNA (lncRNA), promotes lactate production in tumor cells by binding to the lactate dehydrogenase A gene. This lactate production subsequently inhibits NEAT1 expression in CD8+T cells. Furthermore, NEAT1 in CD8+T cells plays a crucial role in modulating the immune response of CD8+T cells against tumor cells. Our findings indicate that NEAT1 regulates the expression of multiple immune checkpoint genes by directly binding to them and inhibiting transcription through the alteration of histone lactylation near transcriptional start sites, which affects RNA polymerase II recruitment. Conclusions: lncRNA NEAT1 serves as a modulator of the antitumor response of CD8+T cells in the bladder tumor microenvironment and may represent a therapeutic target for reversing T-cell exhaustion.
- Open Access
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (2)
Noncanonical functions of UGT2B17 promote castration-resistant prostate cancer progression
Androgen deprivation therapy is the primary treatment for advanced prostate tumors. While initially effective, tumor progression to the therapy-resistant stage is inevitable. Paradoxically, UDP glucuronosyltransferase family 2 member B17 (UGT2B17), the key enzyme responsible for androgen catabolism in prostate tumor cells, is upregulated in therapy-resistant tumors, though its role in tumor progression remains unclear. Here, we demonstrate that UGT2B17 possesses multiple oncogenic functions independent of androgen catabolism. It modulates protein-folding pathways, allowing tumor cells to endure therapy-induced stress. UGT2B17 also regulates transcription associated with cell division and the DNA damage response, enabling unchecked cell proliferation. Targeting the newly identified UGT2B17 functions using a combination of inhibitors reduced tumor growth in therapy-resistant tumor models, highlighting a promising therapeutic strategy. Collectively, these findings reveal a mechanism by which prostate tumors exploit UGT2B17 to evade therapy and highlight its potential as a therapeutic target in advanced prostate cancer.
- 25 November 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (2)
Open AccessNoncanonical functions of UGT2B17 promote castration-resistant prostate cancer progression
Androgen deprivation therapy is the primary treatment for advanced prostate tumors. While initially effective, tumor progression to the therapy-resistant stage is inevitable. Paradoxically, UDP glucuronosyltransferase family 2 member B17 (UGT2B17), the key enzyme responsible for androgen catabolism in prostate tumor cells, is upregulated in therapy-resistant tumors, though its role in tumor progression remains unclear. Here, we demonstrate that UGT2B17 possesses multiple oncogenic functions independent of androgen catabolism. It modulates protein-folding pathways, allowing tumor cells to endure therapy-induced stress. UGT2B17 also regulates transcription associated with cell division and the DNA damage response, enabling unchecked cell proliferation. Targeting the newly identified UGT2B17 functions using a combination of inhibitors reduced tumor growth in therapy-resistant tumor models, highlighting a promising therapeutic strategy. Collectively, these findings reveal a mechanism by which prostate tumors exploit UGT2B17 to evade therapy and highlight its potential as a therapeutic target in advanced prostate cancer.
- Open Access
- 23 October 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (10) , e70445
Dysregulation of Different Modes of Programmed Cell Death in Rheumatoid Arthritis Fibroblast‐Like Synoviocyte
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by chronic synovitis and skeletal joint deformities, often accompanied by systemic symptoms. Over the past few decades, various susceptibility factors for RA have been revealed, and numerous therapeutic drugs have been developed, including analgesics, glucocorticoids, non‐steroidal anti‐inflammatory drugs (NSAIDs), disease‐modifying antirheumatic drugs (DMARDs), and biological agents (bDMARDs). Despite the availability of multiple treatment options, the therapeutic outcomes for some patients remain suboptimal due to the complex pathogenesis of RA. As a key pathological mechanism, programmed cell death (PCD) in RA has received extensive attention. Dysregulation of PCD in RA impacts the progression of the disease. This article systematically reviews the roles of various cell death modalities, including apoptosis, necroptosis, ferroptosis, pyroptosis, and autophagy in the pathophysiology of RA, aiming to provide a theoretical basis and direction for the discovery of new therapeutic targets and drug development.
- 23 October 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (10) , e70445
Open AccessDysregulation of Different Modes of Programmed Cell Death in Rheumatoid Arthritis Fibroblast‐Like Synoviocyte
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by chronic synovitis and skeletal joint deformities, often accompanied by systemic symptoms. Over the past few decades, various susceptibility factors for RA have been revealed, and numerous therapeutic drugs have been developed, including analgesics, glucocorticoids, non‐steroidal anti‐inflammatory drugs (NSAIDs), disease‐modifying antirheumatic drugs (DMARDs), and biological agents (bDMARDs). Despite the availability of multiple treatment options, the therapeutic outcomes for some patients remain suboptimal due to the complex pathogenesis of RA. As a key pathological mechanism, programmed cell death (PCD) in RA has received extensive attention. Dysregulation of PCD in RA impacts the progression of the disease. This article systematically reviews the roles of various cell death modalities, including apoptosis, necroptosis, ferroptosis, pyroptosis, and autophagy in the pathophysiology of RA, aiming to provide a theoretical basis and direction for the discovery of new therapeutic targets and drug development.
- Open Access
- 22 April 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-15
Prostate cancer exploits BRD9-driven metabolic reprogramming to shape the aggressive phenotype
The aggressive phenotype of prostate cancer (PCa) requires adaptation to androgen deprivation (AD) to progress into castration-resistant PCa (CRPC), including adaptation to AD-induced oxidative stress. However, our understanding of the oncogenes that maintain the redox balance during CRPC progression is limited. Here, we identified Bromodomain-containing protein 9 (BRD9) as a metabolic checkpoint for reprogramming cell metabolism to support tumor growth and impart a castration-resistant phenotype under metabolic and oxidative stress. Following oxidation, BRD9 recruited the nuclear transcription factor-Y A-subunit (NFYA) to induce glycogen phosphorylase L (PYGL) expression, which directed glucose utilization through the pentose phosphate pathway, generating NADPH, and promoting clearance of reactive oxygen species (ROS), thus maintaining redox balance. By disturbing redox homeostasis, BRD9 inhibition exerted oxidative pressure on PCa cells, sensitizing them to radiotherapy. This work identified BRD9 as a novel component in antioxidant reprogramming and indicates BRD9 targeting as a promising treatment strategy for PCa therapy.
- 22 April 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-15
Open AccessProstate cancer exploits BRD9-driven metabolic reprogramming to shape the aggressive phenotype
The aggressive phenotype of prostate cancer (PCa) requires adaptation to androgen deprivation (AD) to progress into castration-resistant PCa (CRPC), including adaptation to AD-induced oxidative stress. However, our understanding of the oncogenes that maintain the redox balance during CRPC progression is limited. Here, we identified Bromodomain-containing protein 9 (BRD9) as a metabolic checkpoint for reprogramming cell metabolism to support tumor growth and impart a castration-resistant phenotype under metabolic and oxidative stress. Following oxidation, BRD9 recruited the nuclear transcription factor-Y A-subunit (NFYA) to induce glycogen phosphorylase L (PYGL) expression, which directed glucose utilization through the pentose phosphate pathway, generating NADPH, and promoting clearance of reactive oxygen species (ROS), thus maintaining redox balance. By disturbing redox homeostasis, BRD9 inhibition exerted oxidative pressure on PCa cells, sensitizing them to radiotherapy. This work identified BRD9 as a novel component in antioxidant reprogramming and indicates BRD9 targeting as a promising treatment strategy for PCa therapy.
- Open Access
- 18 February 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 15 (1) , 1-12
CXCR4-targeted PET imaging in rheumatoid arthritis: a novel approach for monitoring disease activity and therapeutic response
Rheumatoid arthritis (RA) is a common chronic, inflammatory autoimmune disease, and early clinical diagnosis is crucial for its treatment. CXCR4 expression was characterized in arthritic mouse models and joints of RA patients, and [18 F]AIF-NOTA-QHA-04 specificity was assessed in non-malignant cells with elevated CXCR4 expression. This study explored the application of CXCR4-targeted PET probe [18 F]AIF-NOTA-QHA-04 in monitoring disease activity and therapeutic efficacy in RA. To this aim, the metabolic characteristics of [18 F]AIF-NOTA-QHA-04 and correlation of [18 F]AIF-NOTA-QHA-04 uptake with arthritis severity were evaluated by PET imaging in arthritic mice. [18 F]AIF-NOTA-QHA-04 potential in evaluating therapeutic efficacy was further investigated in arthritic mice following methotrexate (MTX) and etanercept (ETC) treatment. CXCR4 expression was significantly increased in the inflamed joints of collagen-induced arthritis (CIA) and collagen-antibody induced arthritic (CAIA) mice, and in synovial tissues of RA patients. [18 F]AIF-NOTA-QHA-04 showed high specificity for CXCR4, with increased probe uptake in arthritic joints that was strongly correlated with arthritis severity scores. PET imaging revealed that increased uptake of [18 F]AIF-NOTA-QHA-04 in arthritic joints paralleled disease activity, with uptake decreasing upon remission. Furthermore, [18 F]AIF-NOTA-QHA-04 PET imaging provided earlier and more sensitive assessments of the efficacy of MTX and ETC compared to traditional methods. The CXCR4-targeted PET probe [18 F]AIF-NOTA-QHA-04 is a promising tool for RA diagnosis and monitoring, with high specificity and sensitivity. The potential of this probe as a biomarker for disease activity and therapeutic response underscores its value in personalized medication strategies for the management of RA.
- 18 February 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 15 (1) , 1-12
Open AccessCXCR4-targeted PET imaging in rheumatoid arthritis: a novel approach for monitoring disease activity and therapeutic response
Rheumatoid arthritis (RA) is a common chronic, inflammatory autoimmune disease, and early clinical diagnosis is crucial for its treatment. CXCR4 expression was characterized in arthritic mouse models and joints of RA patients, and [18 F]AIF-NOTA-QHA-04 specificity was assessed in non-malignant cells with elevated CXCR4 expression. This study explored the application of CXCR4-targeted PET probe [18 F]AIF-NOTA-QHA-04 in monitoring disease activity and therapeutic efficacy in RA. To this aim, the metabolic characteristics of [18 F]AIF-NOTA-QHA-04 and correlation of [18 F]AIF-NOTA-QHA-04 uptake with arthritis severity were evaluated by PET imaging in arthritic mice. [18 F]AIF-NOTA-QHA-04 potential in evaluating therapeutic efficacy was further investigated in arthritic mice following methotrexate (MTX) and etanercept (ETC) treatment. CXCR4 expression was significantly increased in the inflamed joints of collagen-induced arthritis (CIA) and collagen-antibody induced arthritic (CAIA) mice, and in synovial tissues of RA patients. [18 F]AIF-NOTA-QHA-04 showed high specificity for CXCR4, with increased probe uptake in arthritic joints that was strongly correlated with arthritis severity scores. PET imaging revealed that increased uptake of [18 F]AIF-NOTA-QHA-04 in arthritic joints paralleled disease activity, with uptake decreasing upon remission. Furthermore, [18 F]AIF-NOTA-QHA-04 PET imaging provided earlier and more sensitive assessments of the efficacy of MTX and ETC compared to traditional methods. The CXCR4-targeted PET probe [18 F]AIF-NOTA-QHA-04 is a promising tool for RA diagnosis and monitoring, with high specificity and sensitivity. The potential of this probe as a biomarker for disease activity and therapeutic response underscores its value in personalized medication strategies for the management of RA.
- Open Access
- 26 January 2025
- Published by Xia & He Publishing in Exploratory Research and Hypothesis in Medicine
- Vol. 000 (000) , 000
E64FC26, a Protein Disulfide Isomerase Inhibitor, Ameliorates Articular Cartilage Damage and Disease Severity in a Mouse Model of Rheumatoid Arthritis
Protein disulfide isomerases (PDIs) are essential enzymes that facilitate the proper folding of proteins and maintain protein quality within the endoplasmic reticulum. Dysregulation of PDIs has been correlated with numerous disorders, including cancer and rheumatoid arthritis (RA). E64FC26 (EFC), a small molecule that inhibits a wide range of PDI family members, has shown promise as a therapeutic agent in oncology. However, its effects on RA have not yet been studied. This research investigates the efficacy of EFC as a potential treatment for RA.
- 26 January 2025
- Published by Xia & He Publishing in Exploratory Research and Hypothesis in Medicine
- Vol. 000 (000) , 000
Open AccessE64FC26, a Protein Disulfide Isomerase Inhibitor, Ameliorates Articular Cartilage Damage and Disease Severity in a Mouse Model of Rheumatoid Arthritis
Protein disulfide isomerases (PDIs) are essential enzymes that facilitate the proper folding of proteins and maintain protein quality within the endoplasmic reticulum. Dysregulation of PDIs has been correlated with numerous disorders, including cancer and rheumatoid arthritis (RA). E64FC26 (EFC), a small molecule that inhibits a wide range of PDI family members, has shown promise as a therapeutic agent in oncology. However, its effects on RA have not yet been studied. This research investigates the efficacy of EFC as a potential treatment for RA.